Introduction

Clinical trials depend on several digital systems working together to manage patient data, treatment assignments, randomization, dispensing, and study operations. Among these systems, Electronic Data Capture (EDC) and Randomization and Trial Supply Management (RTSM) are two of the most critical.

When EDC and RTSM are integrated, information can move between systems without repeated manual entry. This can make study execution faster and more consistent. However, one important question must be answered before integration begins: which system owns each type of data?

Without clear ownership, the same information may be stored or updated in both platforms, creating inconsistencies and reconciliation work. Sponsors and CROs therefore need a well-defined approach to data ownership before configuring an integration between RTSM and EDC software.

Why Data Ownership Matters in EDC and RTSM

Data ownership defines which platform acts as the official source for a specific piece of information.

For example, patient demographics may be entered into Electronic data capture software, while randomization and treatment allocation are generated within RTSM. Although both systems may display some of the same information, only one should normally be responsible for creating or changing it.

This distinction becomes especially important when corrections are required.

If a site changes a patient status in one platform while the same status remains unchanged in another, teams may not know which value is correct. Clear ownership removes that uncertainty.

The objective is to make sure every important data element has one defined system of record.

Identify Where Each Data Element Originates

The first step is to understand where information is originally captured or generated.

In many studies, Electronic data capture software for clinical trials manages clinical information such as demographics, medical history, eligibility data, visit information, adverse events, and clinical outcomes.

RTSM usually manages operational information related to randomization, treatment assignment, kits, inventory, and dispensing.

Before building the integration, sponsors should review all information that needs to move between the platforms.

Each data element should be assigned to one system based on where it is created and which workflow depends on it.

This reduces uncertainty during study execution.

Keep Clinical Data Ownership Within EDC

EDC is generally designed to capture and manage clinical study information.

For this reason, many clinical data elements should remain under the control of Electronic data collection software.

These may include:

• Subject demographics

• Screening information

• Inclusion and exclusion criteria

• Visit completion

• Clinical assessments

• Adverse events

• Laboratory results

• Endpoints

RTSM may need some of this information to perform randomization or dispensing actions. However, receiving the information does not necessarily mean RTSM should own it.

Instead, RTSM can use the data to trigger the appropriate workflow while EDC remains the authoritative source.

This approach helps maintain consistency across the study.

Allow RTSM to Control Randomization Data

Randomization information should generally be controlled by RTSM because it is responsible for assigning patients to treatment groups.

This includes randomization numbers, treatment arms, kit assignments, cohort assignments, and other allocation information.

Once the assignment is created, selected information may be sent back to the EDC software clinical research environment.

The integration must also respect study blinding.

For example, blinded users may need confirmation that randomization has occurred without seeing the actual treatment assignment. Unblinded users may receive additional details depending on their permissions.

Clear ownership helps ensure sensitive treatment information is not unnecessarily exposed.

Establish Rules for Eligibility Information

Eligibility is one of the most sensitive areas in an EDC–RTSM workflow.

Typically, a site enters the required screening information into a Clinical trial data collection software platform. The system evaluates or confirms whether the participant meets the required criteria.

Once eligibility is confirmed, the result may be transferred to RTSM so randomization can take place.

In this scenario, EDC should remain the source of truth for the eligibility status.

RTSM should act on the eligibility information rather than independently creating another version of that data.

This avoids situations where one system identifies a patient as eligible while another shows a different status.

Clearly Define How Data Corrections Work

Corrections must be addressed during integration design.

Consider a patient who has already been randomized. A site later discovers that a stratification value was entered incorrectly.

The value may be corrected in the Clinical trial data capture software, but that correction should not automatically change the treatment assignment.

The integration needs predefined rules explaining what happens next.

Some corrections may simply update EDC. Others may require manual review, notification, or documentation. Certain changes may need to be transferred to RTSM, while others should not trigger any additional action.

These decisions must be defined before study go-live.

Avoid Independent Editing in Both Systems

One of the easiest ways to create inconsistencies is to allow users to edit the same data independently in both EDC and RTSM.

For example, if subject status can be updated separately in both systems, the platforms may eventually contain conflicting information.

A better model is to determine which platform owns the status.

If Data capture software owns the subject status, RTSM should receive the updated value through the integration. Users should not need to make the same change manually in RTSM.

This reduces duplication and helps maintain one consistent patient record.

Consider Data Ownership When Choosing Vendors

Sponsors should also review integration capabilities when evaluating EDC software vendors.

A strong integration should support more than simple data transfer.

Sponsors should understand how the platforms handle failed transactions, duplicate messages, corrected data, audit trails, permissions, and synchronization.

Questions should also be asked about what happens when one system is temporarily unavailable.

Modern EDC clinical trial software should provide clear visibility into integration events so study teams can identify and resolve issues quickly.

This becomes increasingly important in large or complex trials where thousands of transactions may move between systems.

Validate Data Ownership Before Go-Live

Data ownership rules should be thoroughly tested before the study begins.

Teams should test both expected workflows and unusual situations.

For example, they should confirm what happens when eligibility information changes, a randomization request is submitted twice, a transaction fails, a subject discontinues, or a dispensing visit is delayed.

Testing helps confirm that every system behaves according to the agreed ownership model.

It also ensures that the Clinical trial data capture software and RTSM remain synchronized without allowing unauthorized changes.

Conclusion

This buzzingabout  article must have given you a clear understanding of the topic. EDC–RTSM integration works best when every important data element has one clearly defined owner.

Clinical information should typically remain within the Electronic data capture software environment, while RTSM controls randomization, allocation, and supply-related information. The second system can receive and use that information without becoming another independent source.

By defining ownership early, controlling corrections, avoiding duplicate editing, and testing exception scenarios, sponsors can build a more reliable integration.

A well-designed connection between RTSM and EDC software reduces reconciliation effort, improves data consistency, and helps study teams maintain a clear and trustworthy view of patient activity throughout the clinical trial.